DK0929574T3 - Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer - Google Patents

Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer

Info

Publication number: DK0929574T3
Authority: DK; Denmark
Prior art keywords: beta; peptide; amyloid peptide; compounds; amino
Prior art date: 1996-08-27

Application number

DK97940663T

Other languages

English (en)

Inventor

Mark A Findeis

Malcolm L Gefter

Gary Musso

Ethan R Signer

Susan Molineaux

Joseph Chin

Jung-Ja Lee

Michael Kelley

Christopher C Arico-Muendel

James Wakefield

Sonja Komar-Panicucci

Kathryn Phillips

Neil J Hayward

Original Assignee

Praecis Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-27

Filing date

1997-08-27

Publication date

2005-10-31

1996-08-27 Priority claimed from US08/703,675 external-priority patent/US6303567B1/en

1997-08-27 Application filed by Praecis Pharm Inc filed Critical Praecis Pharm Inc

2005-10-31 Application granted granted Critical

2005-10-31 Publication of DK0929574T3 publication Critical patent/DK0929574T3/da

Links

150000008574 D-amino acids Chemical class 0.000 title abstract 4
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title abstract 4
230000006919 peptide aggregation Effects 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 4
125000003368 amide group Chemical group 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 2
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 abstract 1
229930182819 D-leucine Natural products 0.000 abstract 1
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract 1
229930182832 D-phenylalanine Natural products 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
210000004899 c-terminal region Anatomy 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000003367 polycyclic group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Medicinal Chemistry (AREA)
Hospice & Palliative Care (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Zoology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK97940663T 1996-08-27 1997-08-27 Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer DK0929574T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/703,675 US6303567B1 (en)	1995-03-14	1996-08-27	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US89734297A	1997-07-21	1997-07-21
PCT/US1997/015166 WO1998008868A1 (en)	1996-08-27	1997-08-27	MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS

Publications (1)

Publication Number	Publication Date
DK0929574T3 true DK0929574T3 (da)	2005-10-31

Family

ID=27107183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97940663T DK0929574T3 (da)	1996-08-27	1997-08-27	Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer

Country Status (10)

Country	Link
EP (2)	EP0929574B1 (da)
JP (1)	JP2001500852A (da)
AT (1)	ATE298765T1 (da)
AU (1)	AU741199B2 (da)
CA (1)	CA2262453A1 (da)
DE (1)	DE69733655T2 (da)
DK (1)	DK0929574T3 (da)
ES (1)	ES2245003T3 (da)
PT (1)	PT929574E (da)
WO (1)	WO1998008868A1 (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6277826B1 (en)	1996-08-27	2001-08-21	Praecis Pharmaceuticals, Inc.	Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5985242A (en) *	1995-10-27	1999-11-16	Praecis Pharmaceuticals, Inc.	Modulators of β-amyloid peptide aggregation comprising D-amino acids
EP0866805A1 (en)	1995-12-12	1998-09-30	Karolinska Innovations AB	PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6172043B1 (en) *	1997-01-10	2001-01-09	Massachusetts Institute Of Technology	Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
ES2290023T3 (es)	1999-03-04	2008-02-16	Praecis Pharmaceuticals Incorporated	Moduladores de la agregacion del peptido beta-amiloide que comprenden d-aminoacidos.
EP1870419A3 (en) *	1999-03-04	2008-01-02	Praecis Pharmaceuticals Incorporated	Modulators of beta-amyloid peptide aggregation comprising d-amino acids
US7060670B1 (en)	1999-05-05	2006-06-13	Neurochem (International) Limited	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
ATE384077T1 (de) *	1999-05-05	2008-02-15	Neurochem Int Ltd	Stereoselektive antifibrillogene peptide
JP2004513873A (ja) *	1999-11-05	2004-05-13	アクソニックス，インコーポレイティド	アミロイド、アミロイド様沈着物またはそれらのβ−シートリッチな病理前駆体への異常タンパク質折り畳みに関係する疾患の治療における生体内使用に適するペプチド類似物および模倣物
NZ540564A (en) *	1999-11-29	2007-04-27	Neurochem Int Ltd	Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
CA2398567A1 (en) *	2000-02-11	2001-08-16	Praecis Pharmaceuticals Incorporated	Methods for enhancing the bioavailability of a drug
GB2363983A (en)	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) *	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
WO2002035987A2 (en)	2000-11-03	2002-05-10	Massachusetts Institute Of Technology	METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
US7067550B2 (en)	2000-11-03	2006-06-27	Massachusetts Institute Of Technology	Treatments for neurotoxicity in Alzheimer's Disease
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
CA2434831C (en) *	2001-01-17	2012-03-06	Robert H. Zimmer	Polypeptide drug substances
JP4354180B2 (ja) *	2001-12-26	2009-10-28	武田薬品工業株式会社	軽度認知障害治療剤
US20040052928A1 (en)	2002-09-06	2004-03-18	Ehud Gazit	Peptides and methods using same for diagnosing and treating amyloid-associated diseases
PL371366A1 (en)	2002-03-01	2005-06-13	Takeda Pharmaceutical Company Limited	Antidepressant
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US6846640B2 (en)	2002-04-30	2005-01-25	Pharmacia & Upjohn Company	Time-resolved fluorescence assay for the detection of multimeric forms of A-beta 1-40
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
CN101415724B (zh)	2003-06-30	2015-12-02	特拉维夫大学未来科技开发有限公司	肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
ES2396555T3 (es)	2004-12-15	2013-02-22	Janssen Alzheimer Immunotherapy	Anticuerpos que reconocen péptido beta amiloide
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
EP1923388A4 (en)	2005-08-12	2011-03-09	Takeda Pharmaceutical	BRAIN / NEURONAL CELL PROTECTIVE AGENT AND THERAPEUTIC AGENT FOR SLEEP DISORDERS
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
EP2089419A2 (en) *	2006-10-27	2009-08-19	Zapaloid Limited	Inhibition of beta-amyloid aggregation
US7713937B2 (en)	2006-11-10	2010-05-11	Cara Therapeutics, Inc.	Synthetic peptide amides and dimeric forms thereof
US7842662B2 (en)	2006-11-10	2010-11-30	Cara Therapeutics, Inc.	Synthetic peptide amide dimers
US8236766B2 (en)	2006-11-10	2012-08-07	Cara Therapeutics, Inc.	Uses of synthetic peptide amides
PL2064228T3 (pl)	2006-11-10	2013-01-31	Cara Therapeutics Inc	Syntetyczne amidy peptydowe
US8906859B2 (en)	2006-11-10	2014-12-09	Cera Therapeutics, Inc.	Uses of kappa opioid synthetic peptide amides
EP2121633A2 (en)	2007-02-12	2009-11-25	Merck & Co., Inc.	Piperazine derivatives for treatment of ad and related conditions
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
WO2010104194A1 (en)	2009-03-10	2010-09-16	Takeda Pharmaceutical Company Limited	Benzofuran derivatives
CA2813911A1 (en)	2010-10-07	2012-04-12	Takeda Pharmaceutical Company Limited	1,4-oxazepane derivatives
BR112013012033A2 (pt)	2010-11-15	2016-08-09	Merz Pharma Gmbh & Co Kgaa	análogos de dipeptídeos para o tratamento de condições associadas com a formação de fibrila amiloide
CA2851087C (en)	2011-10-07	2019-09-24	Takeda Pharmaceutical Company Limited	1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
WO2014061676A1 (ja)	2012-10-16	2014-04-24	武田薬品工業株式会社	複素環化合物
WO2014092100A1 (ja)	2012-12-11	2014-06-19	武田薬品工業株式会社	複素環化合物
US9598398B2 (en)	2013-04-04	2017-03-21	Takeda Pharmaceutical Company Limited	Heterocyclic compound
EP2982670B1 (en)	2013-04-04	2018-11-07	Takeda Pharmaceutical Company Limited	Heterocyclic compound
JP6533799B2 (ja)	2014-06-09	2019-06-19	武田薬品工業株式会社	放射標識された化合物
EP4438041A3 (en)	2016-02-04	2025-01-01	Takeda Pharmaceutical Company Limited	Substituted piperidine compound and use thereof
EP3594203B1 (en)	2017-03-08	2021-08-04	Takeda Pharmaceutical Company Limited	Substituted pyrrolidine compound and use thereof
WO2019022179A1 (ja)	2017-07-28	2019-01-31	武田薬品工業株式会社	複素環化合物
JP6574918B1 (ja)	2017-08-03	2019-09-11	武田薬品工業株式会社	複素環化合物およびその用途
JP7279067B2 (ja)	2018-03-28	2023-05-22	武田薬品工業株式会社	複素環化合物及びその用途
EP3816154B1 (en)	2018-06-29	2025-04-23	Takeda Pharmaceutical Company Limited	Heterocyclic compound and application thereof
MA54823A (fr)	2019-01-24	2022-04-27	Takeda Pharmaceuticals Co	Composé hétérocyclique et son utilisation
TWI855081B (zh)	2019-05-24	2024-09-11	美商賽吉醫療公司	化合物、組合物及使用方法
KR20220062361A (ko)	2019-09-13	2022-05-16	다케다 야쿠힌 고교 가부시키가이샤	과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도
US20220339143A1 (en)	2019-09-13	2022-10-27	Takeda Pharmaceutical Company Limited	Tak-925 for use in treating narcolepsy
JP2021050161A (ja)	2019-09-25	2021-04-01	武田薬品工業株式会社	複素環化合物及びその用途
JP2021080177A (ja)	2019-11-14	2021-05-27	武田薬品工業株式会社	複素環化合物及びその用途
WO2021106975A1 (ja)	2019-11-27	2021-06-03	武田薬品工業株式会社	複素環化合物
JP2021183587A (ja)	2020-05-22	2021-12-02	武田薬品工業株式会社	複素環化合物
IL303170A (en)	2020-11-25	2023-07-01	Sage Therapeutics Inc	4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
AR125073A1 (es)	2021-03-12	2023-06-07	Takeda Pharmaceuticals Co	Uso de un agonista del receptor de orexina 2 para el tratamiento de una enfermedad o trastorno mediados por orexina
TW202304437A (zh)	2021-04-02	2023-02-01	日商武田藥品工業股份有限公司	食慾激素２受體促效劑對於手術後復原的用途
US20250145947A1 (en)	2021-11-17	2025-05-08	Takeda Pharmaceutical Company Limited	Cell production method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338837A (en) *	1991-12-13	1994-08-16	The Trustees Of Princeton University	Glycosylated steroid derivatives for transport across biological membranes and process for making same
WO1994019692A1 (en) *	1993-02-18	1994-09-01	The General Hospital Corporation	Alzheimer's disease therapeutics
US5854204A (en) *	1995-03-14	1998-12-29	Praecis Pharmaceuticals, Inc.	Aβ peptides that modulate β-amyloid aggregation
EP0866805A1 (en) *	1995-12-12	1998-09-30	Karolinska Innovations AB	PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)

1997
- 1997-08-27 CA CA002262453A patent/CA2262453A1/en not_active Abandoned
- 1997-08-27 DE DE69733655T patent/DE69733655T2/de not_active Expired - Fee Related
- 1997-08-27 EP EP97940663A patent/EP0929574B1/en not_active Expired - Lifetime
- 1997-08-27 WO PCT/US1997/015166 patent/WO1998008868A1/en not_active Ceased
- 1997-08-27 AT AT97940663T patent/ATE298765T1/de not_active IP Right Cessation
- 1997-08-27 JP JP10511914A patent/JP2001500852A/ja not_active Ceased
- 1997-08-27 EP EP05013789A patent/EP1586584A1/en not_active Withdrawn
- 1997-08-27 AU AU42387/97A patent/AU741199B2/en not_active Ceased
- 1997-08-27 DK DK97940663T patent/DK0929574T3/da active
- 1997-08-27 ES ES97940663T patent/ES2245003T3/es not_active Expired - Lifetime
- 1997-08-27 PT PT97940663T patent/PT929574E/pt unknown

Also Published As

Publication number	Publication date
ATE298765T1 (de)	2005-07-15
AU741199B2 (en)	2001-11-22
ES2245003T3 (es)	2005-12-16
AU4238797A (en)	1998-03-19
PT929574E (pt)	2005-11-30
DE69733655D1 (de)	2005-08-04
HK1021741A1 (en)	2000-06-30
WO1998008868A1 (en)	1998-03-05
DE69733655T2 (de)	2006-04-27
EP0929574B1 (en)	2005-06-29
EP1586584A1 (en)	2005-10-19
EP0929574A1 (en)	1999-07-21
CA2262453A1 (en)	1998-03-05
JP2001500852A (ja)	2001-01-23

Publication	Publication Date	Title
PT929574E (pt)	2005-11-30	Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
DK1161449T3 (da)	2007-11-05	Modulatorer af beta-amyloidpeptidaggregering, der omfatter d-aminosyrer
DE69713112D1 (de)	2002-07-11	Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
DK0792287T3 (da)	2004-08-30	Peptidanaloger af humant basisk myelinprotein
ATE417925T1 (de)	2009-01-15	Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
DE69635493D1 (de)	2005-12-29	Verfahren zur herstellung von l-aminosäuren
DE60037800D1 (de)	2008-03-06	Stereoselektive antifibrillogene peptide
ES2071815T3 (es)	1995-07-01	Analogos de delecion de los peptidos conocidos como magaininas.
WO2005060683A3 (en)	2007-04-12	Small peptides for the treatment of alzheimer’s disease and other beta-amyloid protein fibrillogenesis disorders
DK0506748T3 (da)	1996-01-22	Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
DK0896615T3 (da)	2003-01-06	Peptid fra opløselig form af acetylcholinesterase, der er aktivt som calcium-kanal-modulator
ATE167232T1 (de)	1998-06-15	Protein mit knochenbildungs-eigenschaften und verfahren zu seiner herstellung
ES2196088T3 (es)	2003-12-16	Analogos del factor de crecimiento de los queratinocitos.
DE60039049D1 (de)	2008-07-10	Erhöhte expression von proteinen mittels gfp
ATE174932T1 (de)	1999-01-15	Modifizierte vip-derivate und sie enthaltende pharmazeutische zusammensetzungen
DE69706757D1 (de)	2001-10-25	Verfahren zur Herstellung von 3-substituierten Crotonaten
DE69315730D1 (de)	1998-01-29	Verfahren zur Herstellung von Peptiden und neue Zwischenverbindungen dazu
ES2053620T3 (es)	1994-08-01	Derivados de (2-ciano-2-oximinoacetil)-aminoacidos.
EP1870419A3 (en)	2008-01-02	Modulators of beta-amyloid peptide aggregation comprising d-amino acids
DE3886443D1 (de)	1994-02-03	Menschliche Rhinoviruspeptide.
IT1277057B1 (it)	1997-11-04	Peptidi antigenici migliorati
KR950003312A (ko)	1995-02-16	연골세포 단백질
ATE260932T1 (de)	2004-03-15	Verfahren zur isolierung von 1-(n2-((s- ethoxycarbonyl)-3-phenylpropyl)-n6- trifluoracetyl)-l-lysyl-l-prolin (lisinopril(tfa)ethylester, lpe)
DE59602856D1 (de)	1999-09-30	Verfahren zur Herstellung von (R)-tertiär-Leucin
DE69608512D1 (de)	2000-06-29	Verfahren zur Herstellung von benzylsubstituierten Rhodaninederivaten